TP53 and neoplasm: si-hVDAC1 tumour treatment resulted in an elevation (5-6-fold) of p53 levels in tumours derived from U-87MG, A549 or MDA-MB-231 (expressing mutated p53) cells, while the levels of expression of HIF-1α (Figure 6A–F) and c-Myc (Figure 6B–F) were reduced, as revealed by IHC, immunoblotting and q-RT-PCR analyses.